UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 7,
2019
GT Biopharma, Inc.
(Exact
name of Registrant as specified in its charter)
|
Delaware
(State
or other Jurisdiction of Incorporation or
organization)
|
000-08092
(Commission
File Number)
|
94-1620407
(IRS
Employer I.D. No.)
|
310 N. Westlake Blvd
Suite 206
Westlake Village, CA 91362
Phone: (800) 304-9888
(Address,
including zip code, and telephone number, including area code,
of
registrant’s
principal executive offices)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule l 4a- l 2 under the Exchange Act (17 CFR 240. l
4a- l 2)
☐
Pre-commencement
communications pursuant to Rule l 4d-2(b) under the Exchange Act
(17 CFR 240. l 4d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240. l 3e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On January 7, 2019, Anthony
Cataldo was appointed to be a
director of GT Biopharma, Inc. (hereinafter the
“Company”) by the Board of
Directors.
Mr. Cataldo has extensive experience with the Company, having
served on the Board of Directors from July 2014 until November
2018, also serving as Chief Executive Officer from November 2014 to
September 2017 and Executive Chairman of the Board from September
2017 to February 2018 during that time. Mr. Cataldo will serve as
Vice Chairman of the Board.
Prior to joining the Company, from February 2011 until June 2013,
Mr. Cataldo served as Chairman and CEO/Founder of Genesis
Biopharma, Inc. (now known as Iovance Biotherapeutics, Inc.). Mr.
Cataldo is credited with developing the Stage Four Cancer treatment
for melanoma known as Lion/Genesis using assets acquired from the
National Cancer Institute (NIH). Mr. Cataldo also served as
non-executive co-chairman of the board of directors of MultiCell
Technologies, Inc., a supplier of functional, non-tumorigenic
immortalized human hepatocytes from February 2005 until July
2006.
On October 18, 2018, the Company entered into a Consultant
Agreement with Mr. Cataldo. The term of the Consultant Agreement
remains in effect until September 30, 2019. Mr. Cataldo is paid
$25,000 per month during the term of the Agreement.
SIGNATURES
Pursuant
to the requirement of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GT Biopharma, Inc.
|
|
|
|
|
|
|
|
|
Dated:
January 7, 2019
|
|
By:
|
/s/
Raymond W. Urbanski
|
|
|
|
|
|
Raymond
W. Urbanski
|
|
|
|
|
|
Chairman and Chief
Executive Officer
|
|